Strong MTC02 immunostaining was slightly more prevalent in ERG fusion positive prostate cancers, regardless if the ERG status was obtained by IHC or FISH analysis (p < 0.0001 each; Figure 2). The gene discussed is ERG; the disease is prostate carcinoma.